Senior Front-End Engineer

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal. NEW YORK, Jan 12, 2026, 15:29 (EST) - Trading in the regular session. * Shares of Caris Life Sciences dropped roughly 9% in afternoon trading following the release of preliminary revenue numbers for 2025. * The company estimated fourth-quarter revenue around $281 million and full-year revenue near $800 million, though it warned of significant prior-period adjustments affecting these figures. * Caris revealed a new partnership with Everlywell focused on an upcoming early cancer-screening test, with investors awaiting additional details during a JPMorgan conference presentation later Monday. Caris Life Sciences shares dropped roughly 8.5% to $26.08 in afternoon trading, after fluctuating between $25.35 and $29.77 earlier today. Everlywell The update comes amid J.P. Morgan Healthcare Conference week, a time when healthcare firms typically try to recalibrate expectations ahead of earnings season. Investors are focused on whether Caris can maintain its growth pace without relying on one-off factors. Caris faces a tight deadline to control the story. The company is set to present at the conference later Monday, but the stock's steep drop signals that traders are looking for more than just a jump in top-line numbers. Caris reported preliminary fourth-quarter revenue at around $281 million, marking a roughly 116% jump from the previous year. Full-year revenue came in near $800 million, up about 94%. The company said molecular profiling services brought in approximately $270 million in the quarter, which included some $81 million in "prior period true-ups" - accounting adjustments for previous periods. Pharma research and development services added about $11 million. Caris wrapped up 2025 with roughly $802 million in cash, cash equivalents, restricted cash, and marketable securities. It plans to release full results during an earnings call in late February 2026. "2025 was a breakthrough year for Caris as we became a public company," CEO David D. Halbert said. (Caris Life Sciences) Caris announced a partnership with Everlywell to develop Caris Detect, a blood-based multi-cancer early detection (MCED) test. The assay will leverage whole genome sequencing, with a planned rollout in the first half of 2026. Everlywell CEO Julia Cheek said the collaboration aims to "enhance access" to the screening. (Caris Life Sciences) Before the open, the stock was headed in the opposite direction. CAI shares climbed roughly 3.5% in premarket action, hitting $29.50 following the early revenue report, Nasdaq.com said. (Nasdaq) Evercore ISI analyst Vijay Kumar noted in a recent report that "pharma contracting revenue missed expectations, though diagnostics sales beat," according to Investors.com. That same story highlighted sharp fluctuations in diagnostics and med-tech stocks during conference-week updates, underscoring how the JPMorgan meeting can swing sentiment on a headline within minutes. (Investors) That said, there are clear risks. The company flagged these numbers as preliminary and unaudited, leaving room for doubt about how sustainable the quarter's revenue will be once those big true-ups drop out. Plus, new initiatives like the MCED screening test carry their own execution risks - everything from timing to customer adoption remains uncertain. The company's conference presentation is slated for 1:30 p.m. Pacific time on Monday. Investors will be watching closely for clearer insight into revenue streams and demand trends. Following that, the late-February earnings call will serve as the next major event, with Caris set to release audited 2025 results and provide guidance for 2026. As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news. Stock market today. * Coffee prices pressured by weak Brazilian real as arabica falls and robusta modestly rises January 14, 2026, 4:57 PM EST. March arabica (KCH26) closed down 4.25 cents, -1.18%, while March robusta (RMH26) rose 2 points, +0.05%, as traders weighed currency and supplies. A weaker Brazilian real spurred exporter sales, with the real at a one-week low against the dollar. Vietnam's 2025 robusta exports jumped 17.5% to 1.58 MMT, pressuring prices. Earlier in the week, arabica rose on rainfall concerns in Minas Gerais; the region received 26.5 mm, about 29% of the historical average. ICE inventories show tightness for arabica (398,645 bags on Nov 20, later up to 461,829) and for robusta (4,012 lots on Dec 10, up to 4,278). In supply forecasts, Conab raised Brazil's 2025 production to 56.54 million bags. The ICO and FAS outlooks point to mixed factors: world output up about 2% with arabica down, robusta up.

Health-E Commerce(R) announces collaboration with Everlywell to bring lab testing to millions of flexible spending account (FSA) and health savings account (HSA) users. News provided by. DALLAS, Nov. 13, 2025 /PRNewswire/ - Health-E Commerce(R), parent brand to FSA Store(R) and HSA Store(R), the first and leading online stores dedicated to selling exclusively FSA- and HSA-eligible products and services, today announced a new collaboration with Everlywell, a leader in lab testing for consumers. The collaboration will make the Everlywell 360 subscription available to millions of FSA and HSA users seeking accessible, affordable, and actionable ways to take control of their own health. The launch represents a continued expansion of Health-E Commerce's telehealth offerings designed to give consumers more options for managing health and wellness on their own terms, with their tax-free healthcare funds. "Whether you're searching for a diagnosis for a specific health issue or if you want more insights on personal health status, the Everlywell 360 test is a perfect example of how direct-to-consumer lab testing is filling a growing demand for consumers today," said Keri Kaiser, chief revenue officer for Health-E Commerce(R). "The at-home lab testing market has grown more than 20% in the past three years, as consumers seek flexible, affordable health solutions outside of clinical settings. Our continued focus on bringing FSA- and HSA-eligible telehealth to consumers allows individuals and families to turn their pre-tax dollars into meaningful insights for a healthy future." The comprehensive Everlywell 360* test delivers personalized health insights measuring 83 biomarkers, along with a Care Plan and the option for a clinical care consultation with a licensed physician. All Everlywell tests are processed through a certified laboratory for actionable results you can trust. With over 60 million people nationwide relying on Everlywell for affordable lab testing, the company is removing barriers associated with traditional care, such as high cost and limited appointment availability. "Lab testing should be personalized, convenient, and affordable. And that's what Everlywell is all about: giving people access to health insights that help them better manage their health, even before symptoms start," said Matt O'Connor, general manager, Everlywell. "We're proud to collaborate with Health-E Commerce to give millions of consumers an opportunity to use their FSA and HSA funds on Everlywell 360, gaining trusted health information and personalized guidance without the runaround." About Health-E Commerce Health-E Commerce(R) is the parent brand to FSA Store(R) and HSA Store(R), online stores that serve the 70+ million consumers enrolled in pre-tax health and wellness accounts. The company also created Caring Mill(R), a popular private-label line of health products through which a portion of every purchase is donated to the Children's Health Fund. Since 2010, the health-E Commerce brands have led the direct-to-consumer e-commerce market for exclusively pre-tax health and wellness benefits. Health-E Commerce plays an essential role in advocating for expanded eligibility of important new products and telehealth services within the list of eligible medical expenses. About Everlywell Everlywell is a digital health company pioneering the next generation of biomarker intelligence - combining AI-powered technology with human insight to deliver personalized, actionable health answers. Everlywell transforms complex biomarker data into life-changing insights - seamlessly integrating advanced diagnostics, virtual care, and patient engagement to reshape how and where health happens. Over the past decade, Everlywell has delivered close to 1 billion personalized health insights, transforming care for 60 million people and powering hundreds of enterprise partners. In 2024 alone, an estimated 1 in 86 U.S. households received an Everlywell test, solidifying its spot as the #1 at-home testing brand in the country. Fueled by AI and built for scale, Everlywell is breaking down barriers, closing care gaps, and unlocking a more connected healthcare experience that is smarter, faster, and more personalized. Learn more at everlywell.com. *Everlywell offers health and wellness solutions including laboratory testing for wellness monitoring, informational, and educational use. With the exception of certain diagnostic panels, the tests offered are not intended to diagnose or treat disease and are not available in New York. Consumers should check with their FSA or HSA administrator for documentation requirements before purchasing. SOURCE Health-E Commerce more press release views with

Everlywell launches next-gen AI health platform Eva to power smarter, scalable care. Enterprise-ready AI solution built with Everlywell's signature speed and precision AUSTIN, Texas, October 02, 2025-(BUSINESS WIRE)-Everlywell, a leader in digital health, today announced the launch of Eva - an AI-powered platform that turns complex biomarker data into easy-to-understand, personalized health insights. Eva combines intelligence with engaging tools to guide and motivate individuals to take meaningful action for their health. Eva is an intelligent health companion that helps personalize crucial touchpoints with smart recommendations and insights throughout the healthcare journey, including an AI-powered engagement model, care plans and clinician support, and CX agent: * Eva Engage: AI-powered proactive outreach that connects people at the right time with the right care, automatically scaling personalized health engagement for enterprise partners, including health plans and employers. * Eva Care: Smart care coordination that helps create personalized treatment pathways and connects people seamlessly with Everlywell's affiliated provider network. * Eva Support: Comprehensive AI navigator that instantly handles product questions, technical support, account management, and customer service needs. Designed to reshape how and where healthcare happens, Eva integrates diagnostics, virtual care, and engagement into one seamless, end-to-end experience. With billions of engagement data points, Everlywell's platform powers predictive outreach and dynamic care plans - fueling measurable outcomes for consumers and efficiency for enterprise partners. Later this year, Everlywell will expand Eva's capabilities to streamline clinician workflows, including clinical charting and documentation. For enterprise partners, Eva will guide a member through their entire care journey. A member who has never measured their blood pressure before, for example, can be engaged with personalized communications from Eva Engage, guided to the right blood pressure monitoring device by Eva Care with results interpreted instantly and a tailored care plan from a clinician - all in one connected care journey with Eva. "We defined accessible, simple lab testing over the past decade - delivering health insights to 60 million Americans - and now we're deploying the intelligence layer that healthcare has been missing," said Julia Cheek, Founder and CEO of Everlywell. "This is proactive, personalized care powered by AI and grounded in clinical rigor. We're not replacing human insight. We're using AI-powered technology to scale it." Already embedded across Everlywell's care ecosystem, Eva has delivered a measurable impact in patient engagement, clinical efficiency, and care gap closure. Everlywell 360 care plans are more insightful than ever with AI-enhanced, clinician-reviewed insights, and consumer engagement rates have more than doubled with Eva Support. For enterprise partners, this will mean higher return rates, lower costs per member, and a smooth experience that keeps patients engaged in their health journey - powered by machine learning models and voice agentic AI engagement.